Specifically, this therapy appears less effective in conditions with lower FAP expression, such as melanoma and renal cell carcinoma (RCC), while showing increased effectiveness in conditions with high FAP expression, notably cervical cancer. This evidence concerns the gene FAP and cervical carcinoma.